Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127104 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL26213 | 0.80 | CYP1A2 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL2838141 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL6240981 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL29560700 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL330100 | 0.78 | SIGMAR1 (0.59) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL130253 | 0.76 | SIGMAR1 (0.58) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL5900962 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL7439598 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL11719313 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4257577-A2 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-10-11 | — | — | EP | disclosed |
| CN-109803956-B | Novel benzamide compound, process for producing the same, and acaricide | 日本欧爱特农业科技株式会社 | 2023-08-29 | — | — | CN | disclosed |
| US-11649206-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | UNIVERSITY OF HAWAII | 2022-12-29 | — | — | US | disclosed |
| EP-3484855-B1 | NOVEL BENZYLAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND MITICIDE | OAT AGRIO CO LTD (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11254700-B2 | GSK-3β inhibitors and use thereof in methods of treatment | UNIVERSITY OF HAWAII (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021261471-A1 | THERAPEUTIC AGENT FOR OBSESSIVE-COMPULSIVE DISORDER | 国立大学法人京都大学 | 2021-12-30 | — | — | WO | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-5032588-A | Non-steroidal antiinflammatory | ABBOTT LABORATORIES (US) | 1991-07-16 | — | — | US | disclosed |
| WO-1991008744-A1 | THIAZOLE LIPOXYGENASE-INHIBITING COMPOUNDS DERIVED FROM NON-STEROIDAL ANTIINFLAMMATORY CARBOXYLIC ACIDS | ABBOTT LABORATORIES (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0377139-A1 | N-substituted acylamino acid compounds, process for their production and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1990-07-11 | — | — | EP | disclosed |
| CN-1040982-A | Nitragin (rhizoxin) derivative and as antineoplastic agent | SANKYO CO (JP) | 1990-04-04 | — | — | CN | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| EP-0214708-B1 | GRISEOLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANKYO COMPANY LIMITED (JP) | 1989-12-13 | — | — | EP | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | COASY, HAGH, MRM1 | CYP1A2 642/4885CYP2A6 611/4885HTR2A 4394/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CYP1A2 148/4885CYP2A6 46/4885HTR2A 2670/4885 |
| US-11254700-B2 | GSK-3β inhibitors and use thereof in methods of treatment | GSK3B, GSK3A, GSKIP | CYP1A2 799/4885CYP2A6 877/4885HTR2A 3317/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | CYP1A2 254/4885CYP2A6 406/4885HTR2A 416/4885 |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | HPD, PPOX, CBR3 | CYP1A2 191/4885CYP2A6 437/4885HTR2A 2083/4885 |
| US-11649206-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | CYP1A2 191/4885CYP2A6 437/4885HTR2A 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.